Citigroup Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $350
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $400 to $350.
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $400 to $350.